NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 55 filers reported holding NUVALENT INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,943,622 | +17.6% | 1,260,466 | +7.9% | 0.00% | 0.0% |
| Q2 2023 | $49,254,096 | +81.0% | 1,167,989 | +12.0% | 0.00% | +50.0% |
| Q1 2023 | $27,217,166 | -45.1% | 1,043,203 | -37.4% | 0.00% | +100.0% |
| Q4 2022 | $49,616,338 | +766.2% | 1,666,096 | +465.5% | 0.00% | – |
| Q3 2022 | $5,728,000 | +48.5% | 294,632 | +3.6% | 0.00% | – |
| Q2 2022 | $3,856,000 | +22.6% | 284,359 | +25.6% | 0.00% | – |
| Q1 2022 | $3,145,000 | -1.9% | 226,439 | +34.4% | 0.00% | – |
| Q4 2021 | $3,207,000 | +2.4% | 168,453 | +21.3% | 0.00% | – |
| Q3 2021 | $3,132,000 | – | 138,911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
| Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
| COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
| Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
| Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
| Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
| Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
| Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |